Rayner have announced they have acquired Omidria from Omeros Corporation, a pharmaceutical drug which supports the maintenance of a dilated pupil during surgery. It protects the eye from cystoid macular oedema and reduces post-operative pain without using opioids. “Our strategic focus is on visual outcomes and patient safety through a range of surgical products and eye drops. The inclusion of Omidria into the portfolio makes perfect sense and I am particularly excited to see the Omidria commercial team join Rayner,” said Tim Clover, Rayner’s CEO.
Katena have announced that they are joining Corza Medical, expanding Corza Medical’s portfolio of surgical products, adding to their breadth of product and adding infrastructure to their ophthalmic surgery segment. “The addition of Katena is highly complementary to our existing surgical product portfolio. This acquisition underscores our dedication to serving our customers with differentiated, high-performance technologies paired with world-class service” Greg Lucier, Executive Chairman of Corza. “The acquisition of Katena further enables us to execute on our mission with high-quality products that allow our customers to maintain, improve and restore sight for their patients.” Dan Croteau, CEO of Corza.
Leave a Reply.
James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.